ArticleAnimal models and experimental medicine2026
Establishment and characterization of mouse lymph node fibrosis models.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLymph node (LN) fibrosis occurs in a variety of pathological conditions, including HIV infection, obesity, cancer, and tissue injury. Fibroblastic reticular cells (FRCs) play a critical role in maintaining LN architecture and immune homeostasis, whereas their dysregulation promotes extracellular matrix (ECM) deposition and immune dysfunction. Transforming growth factor-β1 (TGF-β1) is a key profibrotic cytokine. However, reliable and convenient animal models for investigating LN fibrosis remain limited.
methodsThis study comprehensively compared four induction methods: footpad injection of TGF-β1, lymphatic vessel ligation, inguinal subcutaneous injection of TGF-β1, and direct intra-LN injection of TGF-β1. Histological analysis, transcriptomic profiling, flow cytometric analysis, and safety evaluation were performed to assess fibrosis and immune alterations.
resultsAmong the four approaches, inguinal subcutaneous and intra-LN injection of TGF-β1 successfully induced LN fibrosis without causing significant injury to major organs. Notably, the intra-LN injection model induced fibrosis in both cortical and medullary regions of LNs. Comparing the transcriptomic data of fibrotic and non-fibrotic LNs demonstrated marked changes in fibrosis-related genes, including pro-fibrogenic mediators, collagens and basement membrane-related genes, and TGF-β1-associated signaling pathways. In two fibrotic models, we also noticed increased macrophage infiltration and a drop in CD8
conclusionWe established and characterized two mouse models of LN fibrosis induced by TGF-β1 administration. These models provide valuable tools for investigating the mechanisms of LN fibrosis and its impact on local immune regulation, and may facilitate the development of therapeutic strategies targeting fibrotic LNs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.